Hypertension in a Randomized Trial of Dolutegravir- Versus Efavirenz-Based Antiretroviral Therapy in Pregnant and Postpartum Women with HIV
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag245 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Risa Hoffman und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at the University of California, Los Angeles, California, US…. Hauptthemen laut MEDLINE: HIV Infections, Benzoxazines, Heterocyclic Compounds, 3-Ring, Anti-HIV Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH Common Fund, Office of AIDS Research, NICHD.
Abstract (Originalsprache)
Introduction
We performed an analysis of incident hypertension in a randomized trial comparing dolutegravir (DTG) + emtricitabine (F)/tenofovir alafenamide (TAF) versus DTG + F/tenofovir disoproxil fumarate (TDF) versus efavirenz (EFV)/F/TDF in pregnant and postpartum women with HIV.
Methods
Women were randomized at 14–28 weeks gestational age (GA) to start DTG + F/TAF, DTG + F/TDF, or EFV/F/TDF and followed through 50 weeks postpartum. The composite incident hypertension outcome was defined as initiation of antihypertensive medication or ≥2 elevated blood pressures categorized as elevated (130–139 and/or 80–89 mmHg), mild (140–159 and/or 90–99 mmHg), moderate (≥160–179 and/or ≥100–109 mmHg), and severe (≥180 and/or ≥110 mmHg). Incident gestational hypertension was defined by initiation of antihypertensive medication or ≥2 blood pressures ≥ 140 and/or ≥90 mmHg at ≥20 weeks GA with resolution by 12 weeks postpartum. Cox proportional hazard models were used for by-arm comparisons of the composite outcome and to look for the effect of weight change within arm.
Results
Of 626 women without baseline hypertension (median age 26.6 years), the composite incident outcome occurred in 49% (n = 308), predominantly due to the incident elevated category of elevated blood pressure, with no significant differences by arm, although hypertension was numerically more likely in the DTG arms. Each additional 5 kg of weight was associated with an 8%–17% higher hazard of the composite hypertension outcome. Twenty-seven participants (4.3%) had gestational hypertension with no apparent differences between arms.
Conclusions
Our data contribute information regarding the safety of DTG-based ART and TAF in pregnant and postpartum women and highlight the importance of monitoring weight and performing hypertension screening as part of maternal health care for young women with HIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- University of North Carolina Project-Malawi, Lilongwe, Malawi.
- Division of Global Women's Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Faculty of Medicine and Health Sciences, University of Zimbabwe Clinical Trials Research Unit, Harare, Zimbabwe.
- Instituto de Puericultura e Pediatria Martagão Gesteira, IPPMG, UFRJ, Rio de Janeiro, Brazil.
ORCID-Profile: Risa Hoffman, Lameck Chinula, Lynda Stranix-Chibanda, Gaerolwe Masheto, Roger Shapiro, Sherika Hanley, Shahin Lockman
Förderung
- NIH Common Fund
- Office of AIDS Research
- NICHD
- Developing Research Innovation, Localisation and Leadership
- National Institute of Child Health and Human Development
- NIAID NIH HHS
- NIH HHS
- FIC NIH HHS
Zitieren
APA
Hoffman, R., Brummel, S., Pinilla, M., Malonga, G., Chinula, L., Stranix-Chibanda, L., Machado, E. S., Naik, S., Rathore, M. H., Pilotto, J., Masheto, G., Stringer, J. S. A., Shapiro, R., Mitchell, C. D., McCarthy, K., João, E. C., Cressey, T. R., Hanley, S., Jean-Philippe, P., …, & IMPAACT 2010/VESTED Study Team (2026). Hypertension in a Randomized Trial of Dolutegravir- Versus Efavirenz-Based Antiretroviral Therapy in Pregnant and Postpartum Women with HIV. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag245
Vancouver
Hoffman R, Brummel S, Pinilla M, Malonga G, Chinula L, Stranix-Chibanda L, et al. Hypertension in a Randomized Trial of Dolutegravir- Versus Efavirenz-Based Antiretroviral Therapy in Pregnant and Postpartum Women with HIV. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag245
BibTeX
@article{Hoffman2026,
author = {Hoffman, Risa and Brummel, Sean and Pinilla, Mauricio and Malonga, Grace and Chinula, Lameck and Stranix-Chibanda, Lynda and Machado, Elizabeth S and Naik, Shilpa and Rathore, Mobeen H and Pilotto, Jose and Masheto, Gaerolwe and Stringer, Jeffrey S A and Shapiro, Roger and Mitchell, Charles D and McCarthy, Katie and João, Esaú Custódio and Cressey, Tim R and Hanley, Sherika and Jean-Philippe, Patrick and Stotz, Chelsea and Sax, Paul and Currier, Judith S and Lockman, Shahin and IMPAACT 2010/VESTED Study Team, IMPAACT 2010/VESTED Study Team},
title = {Hypertension in a Randomized Trial of Dolutegravir- Versus Efavirenz-Based Antiretroviral Therapy in Pregnant and Postpartum Women with HIV},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag245}
}
EUVIMED